CN102277330B - Human CD3+CD8+gamma delta T lymphocyte, as well as preparation method and application thereof - Google Patents
Human CD3+CD8+gamma delta T lymphocyte, as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102277330B CN102277330B CN2011101625783A CN201110162578A CN102277330B CN 102277330 B CN102277330 B CN 102277330B CN 2011101625783 A CN2011101625783 A CN 2011101625783A CN 201110162578 A CN201110162578 A CN 201110162578A CN 102277330 B CN102277330 B CN 102277330B
- Authority
- CN
- China
- Prior art keywords
- lymphocyte
- people
- human
- culture media
- special culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a human CD3+CD8+gamma delta T lymphocyte, as well as a preparation method and application thereof. The T lymphocyte is a human T lymphocyte expressing the following three T lymphocyte membrane molecules: a human leukocyte differentiation antigen CD3, a human leukocyte differentiation antigen CD8 and a human gamma delta T cell receptor. The human CD3+CD8+gamma delta T lymphocyte combined with the traditional operation, chemotherapy and radiotherapy can eliminate and kill little residual or spreading tumor cells by using a biological therapy mode after massive tumor cells are eliminated by a convention therapy method so as to achieve the aims of improving and consolidating tumor treatment effect and reducing tumor recurrence.
Description
Technical field
The present invention relates to a kind of T lymphocyte and preparation method thereof and application, particularly a kind of people CD3
+CD8
+ γ δT lymphocyte and preparation method thereof and application.
Background technology
Lymphocyte is the clone with specific immune recognition function, and the lymphocyte series of people and mammal is made up of plesiomorphism, the different heterogeneity cell mass of function.Press the different of its individual generation, surface molecular and function, lymphocyte series can be divided into T cell and two subgroups of B cell.T cell wherein is made up of the different heterogeneous lymphocyte of a group function, because its differentiation and maturation event in thymus gland is called the T cell.Mature T cells is moved out by thymus gland, migrate the paracortex of lymphatic node in the peripheral lymphoid tissue and splenic white pulp arteriolar around.The T cell of difference in functionality maturation all belongs to small lymphocyte, can not distinguish on morphology, but can borrow its surface of cell membrane molecule difference to be differentiated.At stationary phase and pot-life, kind and quantity that its membrane molecule is expressed are all inequality in T cell development different steps and mature T cells.Because these molecules are at T cell surface quite stable, thus can be considered the surface marker of T cell, can be in order to separate, to identify the T cell of difference in functionality.The monoclonal antibody of these molecules also has significant application value to diagnosis and the treatment of clinical relative disease.Wherein, TCR (T cell receptor) is the specific receptors of T cell recognition proteantigen, and the molecular structure of different its antigen recognition receptors of T cell clone also is inequality.TCR has two types, forms by two different polypeptide chains of striding film, i.e. α β TCR and gamma delta T CR.The α β TCR molecule that the TCR molecule of most of mature T cells (accounting for 95%) is made up of α and two heterodimer peptide chains of β.TCR γ delta cell be more common in earlier T cell in the thymus gland (CD4-, CD8-, TCR γ δ+), and around the people in the blood mature T cells (CD3+, TCR γ δ+) shared ratio very few, be about 1%～10%.This newfound T cells physiological function be it be unclear that.
Summary of the invention
The purpose of this invention is to provide a kind of new human T lymphocyte.
Human T lymphocyte provided by the present invention, title behaviour CD3
+CD8
+ γ δThe T lymphocyte is expressed as follows three kinds of T lymphocyte membrane molecules: human leukocyte differentiation antigen CD3, human leukocyte differentiation antigen CD8 and people
γ δTXi Baoshouti.
Experiment showed, people CD3
+CD8
+ γ δThe T lymphocyte can tumor remission radiotherapy and/chemotherapy due to bone marrow depression.With people CD3
+CD8
+ γ δThe T lymphocyte be activeconstituents tumor remission radiotherapy and/chemotherapy due to myelosuppressive product also belong to protection scope of the present invention.
Experiment showed, people CD3 of the present invention
+CD8
+ γ δT lymphocyte combined with chemotherapy and/or radiotherapy can make lung cancer primary lesion and metastatic lesion dwindle, and make lung carcinoma cell shift thoracic vertebrae, lung carcinoma cell transfer centrum and lung carcinoma cell transfer rib and harden gradually.With people CD3
+CD8
+ γ δThe T lymphocyte is medicine or the product of the treatment tumour of activeconstituents, and activeconstituents comprises chemotherapeutics and the people CD3 that treats tumour
+CD8
+ γ δComplete medicine or the complete sets of products of the lymphocytic treatment tumour of T all belong to protection scope of the present invention.
Described tumour specifically can be lung cancer, cancer of the stomach or colorectal carcinoma.
Above-mentioned people CD3
+CD8
+ γ δThe T lymphocyte can be according to the preparation of the method that comprises the steps: the human peripheral blood single nucleus cell that exsomatizes as people CD3 down
+CD8
+ γ δCultivate and go down to posterity in the T lymphocyte special culture media and obtain people CD3
+CD8
+ γ δThe T lymphocyte: add the substratum that human plasma, isopentenylpyrophosphate and Human Inter Leukin-2 obtain in RPMI 1640 substratum, described human plasma is at described people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 10% (concentration expressed in percentage by volume), and described isopentenylpyrophosphate is at described people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 100 μ g/L, and described Human Inter Leukin-2 is at people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 600,000 U/L.
Wherein, described human plasma specifically can be people AB blood plasma.Described RPMI 1640 substratum can obtain from commercial channels, as can be RPMI 1640 substratum that GENMED company production code member is GMS12049.2A.
Wherein said stripped human peripheral blood single nucleus cell is at described people CD3
+CD8
+ γ δGo down to posterity more than 5 generations in the T lymphocyte special culture media.
Above-mentioned cultivation and go down to posterity all can be at 37 ℃, 5%CO
2In carry out.
People CD3 of the present invention
+CD8
+ γ δThe T lymphocyte cooperates traditional operation, chemotherapy and radiation treatment, can reach after routine treatment is removed the massive tumor cell, re-use the biology therapeutic modality and remove, kill and wound the tumour cell of a spot of residual or diffusion, to improve, to consolidate the effect of oncotherapy, reduce the purpose of tumor recurrence.
Description of drawings
Fig. 1 is the male patient people CD3 in 2 years of lung cancer medical history
+CD8
+ γ δCT examination contrast before and after the treatment of T lymphocyte.Arrow shows lung cancer focus and metastasis
A is the CT examination result of lung window
A last left side is the people CD3 that 2009.08.04 day infusion embodiment 1 separates
+CD8
+ γ δResult before the T lymphocyte
The last right side is the CT examination result of 2009.09.22 day
Bottom left is the CT examination result of 2009.11.19 day
Bottom right is the CT examination result of 2010.03.07 day
B is the CT examination result of mediastinum window
A last left side is the people CD3 that 2009.08.04 day infusion embodiment 1 separates
+CD8
+ γ δResult before the T lymphocyte
The last right side is the CT examination result of 2009.09.22 day
Bottom left is the CT examination result of 2009.11.19 day
Bottom right is the CT examination result of 2010.03.07 day
C is for shifting the CT examination result that the thoracic vertebrae focus is hardened gradually
Be followed successively by the people CD3 that 2009.08.04 day infusion embodiment 1 separates from left to right
+CD8
+ γ δResult, the CT examination result of 2009.09.22 day, the CT examination result of 2009.11.19 day and the CT examination result of 2010.03.07 day before the T lymphocyte
D is for shifting the CT examination result that rib diminishes gradually and hardens
Be followed successively by the people CD3 that 2009.08.04 day infusion embodiment 1 separates from left to right
+CD8
+ γ δResult, the CT examination result of 2009.09.22 day, the CT examination result of 2009.11.19 day and the CT examination result of 2010.03.07 day before the T lymphocyte
E is for shifting the CT examination result that centrum hardens gradually
Be followed successively by the people CD3 that 2009.08.04 day infusion embodiment 1 separates from left to right
+CD8
+ γ δResult, the CT examination result of 2009.09.22 day, the CT examination result of 2009.11.19 day and the CT examination result of 2010.03.07 day before the T lymphocyte
F is each thoracic vertebrae sclerotin destruction region CT examination result of increase in density sclerosis gradually
Be followed successively by the people CD3 that 2009.08.04 day infusion embodiment 1 separates from left to right
+CD8
+ γ δResult, the CT examination result of 2009.09.22 day, the CT examination result of 2009.11.19 day and the CT examination result of 2010.03.07 day before the T lymphocyte
Fig. 2 is the women patient people CD3 in 6 years of lung cancer medical history
+CD8
+ γ δCT examination contrast before and after the treatment of T lymphocyte
Fig. 3 A is people CD3
+CD8
+ γ δThe T lymphocyte detects the expression of human leukocyte differentiation antigen CD3 by flow cytometer
Fig. 3 B is people CD3
+CD8
+ γ δThe T lymphocyte detects the expression of human leukocyte differentiation antigen CD8 by flow cytometer
Fig. 3 C is people CD3
+CD8
+ γ δThe T lymphocyte detects the people by flow cytometer
γ δThe expression of TXi Baoshouti
Embodiment
Employed experimental technique is ordinary method if no special instructions among the following embodiment.
Used material, reagent etc. if no special instructions, all can obtain from commercial channels among the following embodiment.
RPMI 1640 is the product of GENMED company, and its production code member is GMS12049.2A; People AB blood plasma is available from BJ Red Cross Blood Center; Injection recombinant human interleukin--2 (the accurate word S10970016 of traditional Chinese medicines).
Embodiment 1, people CD3
+CD8
+ γ δThe lymphocytic separation of T
Be placed in the large capacity refrigerated centrifuge after people's three bag blood trims of 1) blood station being gathered in 6-8h, with centrifugal force 1160Xg, 4 ± 2 ℃ of temperature, centrifugal 8 minutes.
2) take out the blood bag gently after the shutdown and place on the plasma-separating clip, upper plasma is clamp-oned in the transfering bag together with the tunica albuginea layer and near the red corpuscle of tunica albuginea layer 1.5-2.0cm.
3) with whizzer preheating on request (22 ± 2 ℃ of temperature).
4) with becoming few slurry blood in the Precerving liquid adding red corpuscle in the multi-joint bag, will starch blood less with high-frequency thermocompressor and cut off.After the trim of residue bigeminy bag, change 22 ± 2 ℃ of temperature, centrifugal 8 minutes with 3500.
5) tell upper plasma to transfering bag after centrifugal, stay about 15ml blood plasma, remaining blood plasma and tunica albuginea layer are the white corpuscle platelet suspension.
6) preparation finishes, and goes into storehouse to be checked after the microcomputer typing immediately and preserves in 22 ± 2 ℃ of thrombocyte vibration preservation casees.The preservation validity period is 24h.
7) adopt the Ficoll-hypaque method to isolate mononuclearcell (PBMC) from the white corpuscle platelet suspension.Concrete grammar is as follows: with PBS with 1 times of dilution of white corpuscle platelet suspension after, be added on the Ficoll-hypaque parting liquid, the white corpuscle platelet suspension of dilution: parting liquid is about 1: 1.After centrifugal with the centrifugal 20min of 2000r/min with horizontal centrifuge, mononuclearcell is positioned at the interfacial layer of blood plasma and parting liquid, draws interface mononuclearcell layer, washes secondary with the centrifugal 10min of PBS dilution back 2000r/min.
8) PBMC that separates is incubated at 37 ℃, 5%CO
2Incubator, nutrient solution behaviour CD3
+CD8
+ γ δT lymphocyte special culture media.This people CD3
+CD8
+ γ δT lymphocyte special culture media is to add the substratum that people AB blood plasma, isopentenylpyrophosphate and Human Inter Leukin-2 (IL-2) obtain in RPMI 1640 substratum, and people AB blood plasma is at this people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 10% (concentration expressed in percentage by volume), and isopentenylpyrophosphate is at this people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 100 μ g/L, and the Human Inter Leukin-2 is at this people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 600,000 U/L.This people CD3
+CD8
+ γ δThe pH of T lymphocyte special culture media is 7.2-7.4.Every 2-3 days at this people CD3
+CD8
+ γ δGo down to posterity once in the T lymphocyte special culture media, make cell concn maintain (5～10) * 10
5Individual cell/mL.The culture condition that at every turn goes down to posterity is 37 ℃, 5%CO
2Passing for 5 generations obtains people CD3
+CD8
+ γ δThe T lymphocyte.This people CD3
+CD8
+ γ δThe T lymphocyte detects the expression of human leukocyte differentiation antigen CD3 by flow cytometer with anti-people CD3 monoclonal antibody, with the expression of anti-people CD8 monoclonal antibody by flow cytometer detection human leukocyte differentiation antigen CD8, detect the people with anti-people TCR γ δ monoclonal antibody by flow cytometer
γ δThe expression of TXi Baoshouti, the result shows this people CD3 shown in Fig. 3 A, Fig. 3 B and Fig. 3 C
+CD8
+ γ δT lymphocyte expressing human leukocyte differentiation antigen CD3, human leukocyte differentiation antigen CD8 and people
γ δTXi Baoshouti.The flow cytometer detected result shows this people CD3
+CD8
+ γ δThe lymphocytic purity of T reaches 95%.
Embodiment 2, people CD3
+CD8
+ γ δThe lymphocytic activity of T
All through the chemotherapy of a course for the treatment of 53 routine tumour patients in (week 1 chemotherapy, totally 6 weeks), be divided into treatment group and control group at random.22 routine tumour patients are organized in treatment, and wherein clinical diagnosis is patients with gastric cancer 5 examples, and clinical diagnosis is colorectal carcinoma patient 6 examples, and clinical diagnosis is patients with lung cancer 11 examples.Control group 31 examples, wherein clinical diagnosis is patients with gastric cancer 7 examples, and clinical diagnosis is colorectal carcinoma patient 8 examples, and clinical diagnosis is patients with lung cancer 16 examples.
The people CD3 that step 1 is obtained
+CD8
+ γ δThe T lymphocyte adds in the aseptic preservation liquid of being made up of the material of following proportioning (anticoagulant for storage of whole blood II) to be preserved: Sodium Citrate (C
6H
5Na
3O
72H
2O) 13.2g, Citric Acid (C
6H
8O
7H
2O) 4.8g, glucose (C
6H
12O
6H
2O) 14.7g and water 1000ml.The pH of this aseptic preservation liquid is 7.2-7.4.People CD3
+CD8
+ γ δThe T lymphocyte is (2-3) * 10 at the content of this aseptic preservation liquid
7The ml of individual cell/(30-50).Preserved 10-12 hour at 4 ℃, as the people CD3 that feeds back to the patient
+CD8
+ γ δT lymphocyte suspension.
22 routine tumour patient chemotherapeutic for the treatment of group stop to give vein in back 72 hours and feed back above-mentioned people CD3
+CD8
+ γ δT lymphocyte suspension.Every above-mentioned people CD3 of the disposable input 30-50ml of patient
+CD8
+ γ δT lymphocyte suspension was totally lost in 30 minutes.Be every above-mentioned people CD3 of the disposable input of patient
+CD8
+ γ δT lymphocyte (2-3) * 10
7Individual cell.The patient of control group does not treat after chemotherapy.Every patient before chemotherapy, chemotherapeutic stops back 72 hours people CD3
+CD8
+ γ δThe T lymphocyte feeds back preceding, people CD3
+CD8
+ γ δThe T lymphocyte feeds back and detected peripheral hemogram WBC, PLT in back 3 days.Data are represented with mean+SD, relatively carry out the t check between two groups.
The result shows, people CD3
+CD8
+ γ δPeripheral blood WBC, PLT that the T lymphocyte feeds back the back tumour patient raise obviously * P＜0.05.People CD3 is described
+CD8
+ γ δThe T lymphocyte can obviously be alleviated bone marrow depression (table 1).
Table 1 treatment group and control group peripheral blood after chemotherapy resemble WBC, PLT changing conditions
Annotate: for control group, " the T cell fed back back 3 days after the chemotherapy " only indicates constantly, and control group does not carry out the T cell therapy.
In the 22 routine tumour patients for the treatment of group, wherein the male patient in 2 years of lung cancer medical history is at the people CD3 of 2009.08.04 day infusion embodiment 1 separation
+CD8
+ γ δThe T lymphocyte.People CD3 in 2009.08.04 day infusion embodiment 1 separation
+CD8
+ γ δBefore the T lymphocyte, carry out 2009.09.22 day, 2009.11.19 day, 2010.03.07 CT after day respectively and detect, the result as shown in Figure 1, show left lung cancer diminish gradually (A and B), lung cancer metastasis thoracic vertebrae harden gradually (C), cancer metastasis centrum harden gradually (E), the cancer metastasis rib hardens gradually, tumour diminish gradually (D); Each thoracic vertebrae sclerotin destruction region density increases sclerosis (F) gradually.
In the 22 routine tumour patients for the treatment of group, wherein the women patient in 6 years of lung cancer medical history stops back 72 hours people CD3 in chemotherapeutic
+CD8
+ γ δ(before the treatment) and people CD3 before the T lymphocyte feeds back
+CD8
+ γ δThe T lymphocyte feeds back back 6 months (treatment back) and carries out the CT detection respectively, and the result shows that this patient's lung cancer primary lesion diminishes as shown in Figure 2.Above-mentioned two cases all visible focus do not have the generation of increase situation, and the tumour primary lesion is suppressed in various degree.
The above-mentioned people CD3 that experimental results show that
+CD8
+ γ δThe T lymphocyte can improve companion's cancerous symptoms such as cancer of the stomach, colorectal carcinoma, lung cancer, promotes lung cancer primary lesion and metastatic lesion to dwindle essentially no untoward reaction.
Claims (2)
1. people CD3
+CD8
+ γ δThe lymphocytic cultural method of T, comprise the steps: the human peripheral blood single nucleus cell that will exsomatize as people CD3 down
+CD8
+ γ δCultivate and go down to posterity in the T lymphocyte special culture media and obtain people CD3
+CD8
+ γ δT lymphocyte: described people CD3
+CD8
+ γ δT lymphocyte special culture media is for to add the substratum that human plasma, isopentenylpyrophosphate and Human Inter Leukin-2 obtain in the RPMI1640 substratum, described human plasma is at described people CD3
+CD8
+ γ δConcentration expressed in percentage by volume in the T lymphocyte special culture media is 10%, and described isopentenylpyrophosphate is at described people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 100 μ g/L, and described Human Inter Leukin-2 is at people CD3
+CD8
+ γ δConcentration in the T lymphocyte special culture media is 600,000 U/L; Described stripped human peripheral blood single nucleus cell is at described people CD3
+CD8
+ γ δGo down to posterity more than 5 generations in the T lymphocyte special culture media.
2. the application of the described method of claim 1 in preparation medicine for treating tumor thing; Described tumour is lung cancer, cancer of the stomach or colorectal carcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101625783A CN102277330B (en) | 2011-06-16 | 2011-06-16 | Human CD3+CD8+gamma delta T lymphocyte, as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101625783A CN102277330B (en) | 2011-06-16 | 2011-06-16 | Human CD3+CD8+gamma delta T lymphocyte, as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102277330A CN102277330A (en) | 2011-12-14 |
| CN102277330B true CN102277330B (en) | 2013-08-28 |
Family
ID=45103065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101625783A Active CN102277330B (en) | 2011-06-16 | 2011-06-16 | Human CD3+CD8+gamma delta T lymphocyte, as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102277330B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103981146A (en) * | 2014-05-29 | 2014-08-13 | 深圳市坤健创新药物研究院 | Group of antitumor T lymphocytes and preparation method thereof |
| CN106434552B (en) * | 2015-08-13 | 2022-04-29 | 清华大学 | Novel NKT-like cell subsets and their use for treating tumors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116549A (en) * | 1994-08-09 | 1996-02-14 | 中国医学科学院肿瘤研究所 | High affinity tumor killer cell (T-AK cell) preparation |
| WO2006017954A1 (en) * | 2004-08-19 | 2006-02-23 | University Of Bern | PREPARATION OF ANTIGEN-PRESENTING HUMAN Ϝδ T CELLS AND USE IN IMMUNOTHERAPY |
-
2011
- 2011-06-16 CN CN2011101625783A patent/CN102277330B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1116549A (en) * | 1994-08-09 | 1996-02-14 | 中国医学科学院肿瘤研究所 | High affinity tumor killer cell (T-AK cell) preparation |
| WO2006017954A1 (en) * | 2004-08-19 | 2006-02-23 | University Of Bern | PREPARATION OF ANTIGEN-PRESENTING HUMAN Ϝδ T CELLS AND USE IN IMMUNOTHERAPY |
Non-Patent Citations (14)
| Title |
|---|
| CIK细胞—肿瘤过继免疫治疗的新希望;于津浦等;《中国肿瘤临床》;20010731;第28卷(第7期);第557-560页 * |
| R.P.Bucy等.Tissue localiztion and CD8 accessory molecule expression of T gamma delta cells in humans.《The Journal of Immunology》.1989,第142卷(第9期),第3045-3049页. |
| Tissue localiztion and CD8 accessory molecule expression of T gamma delta cells in humans;R.P.Bucy等;《The Journal of Immunology》;19890501;第142卷(第9期);第3045-3049页 * |
| γδT淋巴细胞与常规LAK动物学特征性的比较研究;李新燕等;《苏州医学院学报》;19960630;第16卷(第3期);第401-403页 * |
| 于津浦等.CIK细胞—肿瘤过继免疫治疗的新希望.《中国肿瘤临床》.2001,第28卷(第7期),第557-560页. |
| 人γδT细胞过继免疫治疗的临床前研究;张铁;《中国博士学位论文全文数据库/医药卫生科技辑》;20090715(第7期);第12页、18-20页、45-49页、57-58页、66页 * |
| 化疗联合CIK细胞治疗中晚期胃癌的临床疗效评价;张燕等;《肿瘤基础与临床》;20090831;第22卷(第4期);第346-348页 * |
| 异戊烯焦磷酸刺激γδT细胞增殖及体外抗HBV作用;桂万羊等;《临床肝胆病杂志》;20080531;第24卷(第5期);第334-337页 * |
| 张燕等.化疗联合CIK细胞治疗中晚期胃癌的临床疗效评价.《肿瘤基础与临床》.2009,第22卷(第4期),第346-348页. |
| 张铁.人γδT细胞过继免疫治疗的临床前研究.《中国博士学位论文全文数据库/医药卫生科技辑》.2009,(第7期),第12，45-49，57-58，66页. |
| 李新燕等.γδT淋巴细胞与常规LAK动物学特征性的比较研究.《苏州医学院学报》.1996,第16卷(第3期),第401-403页. |
| 桂万羊等.异戊烯焦磷酸刺激γδT细胞增殖及体外抗HBV作用.《临床肝胆病杂志》.2008,第24卷(第5期),第334-337页. |
| 自身细胞因子诱导的杀伤细胞过继性免疫治疗恶性肿瘤的临床观察;陈复兴等;《癌症》;20020731;第21卷(第7期);第797-801页 * |
| 陈复兴等.自身细胞因子诱导的杀伤细胞过继性免疫治疗恶性肿瘤的临床观察.《癌症》.2002,第21卷(第7期),第797-801页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102277330A (en) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors | |
| CN105779386B (en) | A kind of application of mescenchymal stem cell in preparation treatment M5 type leukemia medicament | |
| CN109481666A (en) | A kind of method for building up of blood of human body tumour PDX model | |
| CN102234629B (en) | Special culture medium for human CD3<+>CD8<+gamma delta>T lymphocytes | |
| CN106544365A (en) | A kind of preparation method and application of the CIK of the anti-CD19 Chimeric antigen receptors modification of people | |
| Lin et al. | Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma | |
| CN106222141A (en) | NK cell culture fluid and cell culture processes | |
| Li et al. | 6-Phosphogluconolactonase promotes hepatocellular carcinogenesis by activating pentose phosphate pathway | |
| CN108103026A (en) | γ δ-T cell excretion body for immunotherapy of tumors and preparation method thereof | |
| CN113813255A (en) | Application of urolithin A and derivatives thereof in tumor immunotherapy | |
| CN102277330B (en) | Human CD3+CD8+gamma delta T lymphocyte, as well as preparation method and application thereof | |
| CN102517213B (en) | In vitro culture kit for T-lymphocyte cells | |
| EP2878666A1 (en) | Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes | |
| CN103013914B (en) | Method for in-vitro culture of killer T cells | |
| CN108913709A (en) | For treating the preparation method of the nucleic acid of HCC, preparation method, CAR-T cell and cell with the nucleic acid | |
| CN101914497A (en) | Clinical N-CIK cell culture and quality control and identification kit and application | |
| CN106955352A (en) | Pharmaceutical composition and kit for treating cancer | |
| Liu et al. | Circadian‐rhythm‐regulating hormones: Key factors to regulate breast cancer metastasis via circulating tumor cells | |
| CN102265819B (en) | Preservation method of human CD3+CD8+gamma delta T lymphocytes | |
| CN113875989B (en) | Functionalized water-soluble nano-selenium, preparation method and application | |
| WO2022032665A1 (en) | Method for preparing universal immune cells and use thereof | |
| CN109554296B (en) | In-vitro simulated circulation tumor cell generation device and application thereof | |
| CN108753719B (en) | A method of the LAK LAK of derived from cord blood is improved to tumor-killing power | |
| CN106119192B (en) | Composition and its application in CIK cell culture | |
| CN108314738B (en) | Bispecific chimeric antigen receptor co-expressing cytokine IL-21, plasmid, CIK cell and MM disease application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |